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Abstract
Background: A tenosynovial giant cell tumor (T-GCT) is a benign synovial tumor arising from the synovium, bursae,
or tendon sheath. It can be intra- or extra-articular and localized or diffuse. Diffuse T-GCT is considered as a locally
aggressive. Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose with computed tomography
(FDG PET/CT) is widely used to differentiate malignant from benign tumors and to detect distant metastasis.
However, FDG PET/CT is limited by false-positive findings. In this study, we present two cases of T-GCT that
developed in unusual locations and were confused with malignant tumors. The final diagnoses were histologically
confirmed as T-GCTs.
Case presentation: Case 1. A 45-year-old Japanese female presented with a left choroidal melanoma and an abnormal
lesion adjacent to the first cervical (C1) lamina confirmed by a PET scan (maximum standardized uptake value
[SUVmax] = 9.9 g/ml). MRI of the neck also detected a soft tissue mass (14.6 × 7.7 × 7 mm) adjacent to the C1
lamina. The choroidal melanoma was treated by heavy carbon ion radiotherapy. Although the size of the C1 soft tissue
tumor remained unchanged, a CT-guided biopsy confirmed the diagnosis of the neck mass as a T-GCT.
Case 2. A 15-year-old Japanese male with multiple type 1 neurofibromatosis presented with a soft tissue mass (26.1 ×
24.7 × 11.5 mm) of the extra-articular hip joint that was coincidentally detected by FDG PET/CT during examination of a
mediastinal soft tissue mass. SUVmax of the mediastinal lesion was 2.6 g/ml and of the hip lesion was 12.8 g/ml. Thus,
differentiation from a malignant tumor, such as a malignant peripheral nerve sheath tumor, was necessary. An open
biopsy was performed, and the frozen section was diagnosed as T-GCT. The tumor was excised, and the final
histological diagnosis confirmed T-GCT.
Conclusion: T-GCT can show high FDG uptake, which might be confused with malignancy. Although MRI findings and
location might help in the diagnosis of a T-GCT, careful assessment is mandatory, especially in unusual locations.
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Background
A tenosynovial giant cell tumor (T-GCT) is a benign,
synovial tumor arising from the synovium, bursae, or
tendon sheath. It can be intra- or extra-articular and
localized or diffuse. A localized extra-articular T-GCT is
synonymous with a giant cell tumor of the tendon
sheath; it usually occurs in the hand (other sites include
the wrist, ankle/foot, and knee) and is more often seen
in women than men [1], with a reported annual
incidence of about one in 50,000 [2]. Diffuse T-GCT is
considered as a locally aggressive and predominantly
involves the knee, followed by the hip, ankle, elbow, and
shoulder [3]; it has a reported annual incidence of
approximately two cases per million, mostly younger
than 40 years of age, with no gender predilection [4].
Unusual sites of T-GCTs include extra-articular neck
and hip [5, 6].
Positron emission tomography (PET) with fluorine-18
fluorodeoxyglucose (FDG) with computed tomography
(FDG PET/CT) is widely used to differentiate malignant
from benign tumors and to detect distant metastasis
[7, 8]. However, as on FDG is not cancer-specific,
false-positive findings of benign diseases have been
reported in active inflammation or infection [9–11].
Schulte et al. reported a 15 % false-positive rate of
malignancy among 200 tumor and tumor-like lesions of
the bone [12]. The appearance of T-GCT in FDG
PET/CT was not fully reported because this modality
is not routinely used. However, there are reports of
varied FDG uptake (maximum standardized uptake
value [SUVmax] = 3.43–25 g/ml) in T-GCTs, which
mimic malignant tumors [13–16].
In this article, we discuss two cases of T-GCT that
developed in unusual locations and were initially
thought to be malignant tumors on FDG PET/CT, but
were histologically confirmed as T-GCT.
Case presentation
Case 1
A 45-year-old Japanese woman presented with an ab-
normal lesion in her left eye (Fig. 1) in January 2015.
FDG PET/CT detected mild FDG uptake in the left
choroidal plexus lesion (SUVmax = 3.8 g/ml) and an
Fig. 1 Noncontrast CT detected a high attenuation mass (16 × 11 mm) in the left choroid plexus (a) that showed enhancement after contrast
administration (b)
Fig. 2 FDG PET/CT sagittal image (a) revealed two focal regions
of increased uptake in the eye (white arrow) and posterior neck
(black arrow). Axial image (b) showed increased FDG uptake in
the eye (white arrow) and the choroid plexus of the left eye
(SUVmax = 3.8 g/ml). Axial image (c) of the first cervical (C1)
spine showed increased uptake (black arrow) adjacent to the C2
lamina (SUVmax = 9.9 g/ml)
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intensely hypermetabolic extra-articular soft tissue
density lesion adjacent to the first cervical (C1) lam-
ina (SUVmax = 9.9 g/ml) (Fig. 2). N-isopropyl-p-123I-
iodoamphetamine single-photon emission computed
tomography showed high uptake in the left choroidal
plexus lesion; thus, we arrived at a diagnosis of
choroidal melanoma. Magnetic resonance imaging
(MRI) of the neck detected a soft tissue mass (14.6 ×
7.7 × 7 mm) adjacent to the C1 lamina, demonstrating
an isointense signal on a T1-weighted image (WI),
low signal on a T2WI, and enhanced gadolinium up-
take (Fig. 3). She had no symptom related to the neck
lesion. The choroidal melanoma was treated by heavy
carbon ion radiotherapy from January to March 2015.
The size of the soft tissue tumor of C1 remained
unchanged, and we performed a CT-guided biopsy to
confirm the diagnosis in mid-March 2015. Biopsy spe-
cimen showed small mononuclear stromal cells with
stromal fibrosis, including formation of a hyalinized
collagen matrix and a small area of multinucleated
osteoclast-like giant cells (Fig. 4a). Immunohistochem-
ical analysis showed strong staining for CD68 (Fig. 4b).
The final histological diagnosis was localized T-GCT.
The tumor size remained stable for 6 months after
biopsy, and no functional deficit was detected.
Case 2
A 15-year-old Japanese male was referred to our university
hospital for evaluation of an abnormal lesion of the extra-
articular hip joint in July 2015. He was previously diag-
nosed with multiple neurofibromatosis (neurofibromatosis
type 1; NF-1) and had a history of cleft palate and hydro-
nephrosis at the age of 7 years. A plain chest radiograph
in 2014 had showed mediastinal widening. MRI revealed a
soft tissue mass in the mediastinum. In May 2015, FDG
PET/CT showed low FDG uptake (SUVmax = 2.6 g/ml) in
the mediastinal mass and an intensely hypermetabolic
extra-articular soft tissue density lesion in the left hip
(SUVmax = 12.8 g/ml) (Fig. 5). MRI detected a soft tissue
mass (26.1 × 24.7 × 11.5 mm) located along the proximal
indirect tendon of the rectus femoris muscle, demonstrat-
ing isointense signals on T1- and T2WIs (Fig. 6). He had
no symptom related to the hip soft tissue mass. Because of
the previous diagnosis of NF-1, differentiation from a ma-
lignant tumor, such as a malignant peripheral nerve sheath
tumor, was necessary. A percutaneous core needle biopsy
was performed in June 2015 at the previous hospital,
however the material was insufficient to define the
diagnosis. An open biopsy was performed in July 2015,
and the frozen section was diagnosed as T-GCT. Thus, we
excised the tumor. Excised tumor specimen showed small
Fig. 3 Axial MRI of a soft tissue mass (14.6 × 7.7 × 7 mm) adjacent to the C1 lamina showed isointensity on a T1WI (white arrow) (a), low intensity
on a T2WI (black arrow) (b), and enhanced gadolinium uptake (gray arrow) (c)
Fig. 4 Biopsy specimen showed small mononuclear stromal cells with stromal fibrosis, including formation of a hyalinized collagen matrix and a
small area of multinucleated osteoclast-like giant cells (hematoxylin and eosin staining; scale bar, 100 μm) (a). Immunohistochemical analysis
showed strong staining for CD68 (b)
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mononuclear stromal cells and multinucleated osteoclast-
like giant cells (Fig. 7). The final histological diagnosis was
localized T-GCT. He showed no functional deficit
2 months after the surgery.
Conclusions
T-GCT is a benign soft tissue tumor that arises from the
synovium, bursae, or tendon sheath that typically
contains areas of intermediate and/or low signal inten-
sity on T1- and T2WIs. A T-GCT is usually diagnosed
by MRI [17]. In our patients, the MRI findings were
compatible with T-GCTs, even though the masses were
located in unusual sites. Moreover, FDG PET/CT is not
frequently employed for T-GCT, as the findings cannot
be confirmed. Hamada et al. analyzed FDG PET/CT
images of 56 soft tissue tumors (19 malignant and 37 be-
nign tumors) and found statistically significant difference
in the SUVmax between malignant and benign lesions in
early scans (5.50 ± 5.32 g/ml versus 3.10 ± 2.64 g/ml).
Moreover, the intensities of benign soft tissue lesions
were <6.0 g/ml [18]. Broski et al. reported a mean SUV-
max of 8.7 (range, 4.0–14.5) g/ml for FDG PET/CT
imaging of 14 T-GCTs, and concluded that a T-GCT
could be intensely hypermetabolic, mimicking musculo-
skeletal metastasis [15]. Selby et al. reported a pigmented
villonodular synovitis of the shoulder mimicking a
metastatic melanoma [16]. Lindkog et al. reported false-
positive results of PDG PET/CT in five cases of benign
soft tissue lesions, including two T-GCT lesions, and
mentioned the importance of understanding the limita-
tions of PET, including false-positive findings of benign
lesions [11]. Hamada et al. reported a positive correl-
ation of FDG SUVmax with the expression of GLUT-1
and hexokinase II in 49 musculoskeletal tumors [19].
However, the expression patterns of GLUT-1 and
hexokinase II in T-GCTs have not been fully evaluated.
Therefore, the mechanism of high uptake of FDG PET/
CT in T-GCT remains uncertain. Although FDG PET/
CT is a useful imaging modality for patients with a his-
tory of malignancy and the demand has been increasing,
the chance of detecting benign lesions is also increased.
When a T-GCT is detected in a typical location and MRI
findings are compatible to T-GTC, careful observation
without histological confirmation is reasonable. However,
Fig. 5 Axial FDG PET/CT image (a) showed that the FDG uptake (white arrow) in the mediastinal mass was mild or low-level (a) and high uptake
(black arrow) in the extra-articular soft tissue mass of the left hip (SUVmax = 12.8 g/ml) (b)
Fig. 6 Axial MRI showed a soft tissue mass adjacent to the anterior inferior iliac spine, which was isointense on T1WI (white arrow) (a) and T2WI
(black arrow) (b). Coronal images showed isointensity in T1WI (white arrow) (c) and T2WI with fat saturation image (black arrow) (d)
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if a suspected T-GCT is detected in an unusual location, a
biopsy should be performed for differentiation from a
malignant tumor. Recently, there have been new develop-
ments in the medical treatment of T-GCT using a select-
ive colony-stimulating factor 1 receptor (CSF1R) kinase
inhibitor [20]. FDG PET/CT might be a useful imaging
modality in monitoring this treatment [21].
In conclusion, we encountered two cases of T-GCTs
that developed in unusual locations, which were confused
with malignant tumors. The final diagnoses of these cases
were histologically confirmed as T-GCTs. It is important
to realize that a T-GCT may show high FDG uptake,
which can resemble from a malignant tumor. Although
MRI findings and the location might help to diagnose
a T-GCT, careful assessment is mandatory.
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